LivaNova PLC (NASDAQ:LIVN - Get Free Report) Director Brooke Story sold 2,300 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the transaction, the director directly owned 7,488 shares of the company's stock, valued at approximately $609,672.96. This trade represents a 23.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
LivaNova Trading Down 1.5%
Shares of LIVN stock opened at $80.70 on Wednesday. The company's fifty day simple moving average is $80.63 and its two-hundred day simple moving average is $73.14. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. LivaNova PLC has a 1 year low of $48.82 and a 1 year high of $85.76. The stock has a market capitalization of $4.45 billion, a price-to-earnings ratio of 23.88 and a beta of 0.87.
LivaNova (NASDAQ:LIVN - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The firm had revenue of $390.59 million for the quarter, compared to the consensus estimate of $380.50 million. During the same quarter in the prior year, the business posted $1.05 earnings per share. The business's quarterly revenue was up 10.8% on a year-over-year basis. As a group, analysts anticipate that LivaNova PLC will post 3.77 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the company. Freedom Capital raised LivaNova to a "hold" rating in a report on Tuesday, June 30th. Mizuho increased their price target on shares of LivaNova from $90.00 to $95.00 and gave the stock an "outperform" rating in a report on Wednesday, July 15th. Stifel Nicolaus set a $85.00 price objective on shares of LivaNova in a research report on Wednesday, August 5th. Zacks Research cut shares of LivaNova from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 19th. Finally, Needham & Company LLC upped their target price on shares of LivaNova from $81.00 to $93.00 and gave the stock a "buy" rating in a report on Wednesday, August 5th. Six research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $84.12.
View Our Latest Analysis on LivaNova
Hedge Funds Weigh In On LivaNova
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC bought a new position in LivaNova in the 2nd quarter worth about $1,418,000. Allworth Financial LP boosted its position in shares of LivaNova by 93.5% during the 2nd quarter. Allworth Financial LP now owns 298 shares of the company's stock valued at $25,000 after acquiring an additional 144 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of LivaNova during the 2nd quarter valued at about $4,053,000. California State Teachers Retirement System grew its holdings in shares of LivaNova by 7,996.3% during the second quarter. California State Teachers Retirement System now owns 5,154,505 shares of the company's stock worth $423,855,000 after purchasing an additional 5,090,840 shares in the last quarter. Finally, Turner Financial Group Inc. purchased a new position in shares of LivaNova during the second quarter worth about $392,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
About LivaNova
(
Get Free Report)
LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.
The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
